caseins has been researched along with Cognitive Decline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abu Bakar, ZH; Hamezah, HS; Matsuzaki Tada, A; Pahrudin Arrozi, A; Tooyama, I; Yanagisawa, D | 1 |
| Abe, F; Kakiuchi, I; Kiyosawa, K; Miyasaka, M; Nakamura, M; Sakane, N; Tanaka, M; Yamauchi, K; Yuda, N | 1 |
1 trial(s) available for caseins and Cognitive Decline
| Article | Year |
|---|---|
Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Administration, Oral; Aged; Caseins; Cognition; Cognitive Dysfunction; Double-Blind Method; Female; Humans; Independent Living; Male; Neuropsychological Tests; Nootropic Agents; Oligopeptides; Tablets; Treatment Outcome | 2020 |
1 other study(ies) available for caseins and Cognitive Decline
| Article | Year |
|---|---|
Pharmaceutical Potential of Casein-Derived Tripeptide Met-Lys-Pro: Improvement in Cognitive Impairments and Suppression of Inflammation in APP/PS1 Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Caseins; Cognitive Dysfunction; Disease Models, Animal; Inflammation; Mice; Mice, Inbred C57BL; Mice, Transgenic; NADPH Oxidases; Oligopeptides; Pharmaceutical Preparations; Presenilin-1; Receptors, Angiotensin; Tumor Necrosis Factor-alpha | 2022 |